TIRZEPATIDE 10mg – peptide dimagrante MOUNJARO – DUBAI LABS

Tirzepatide: Overview and Mechanism of Action

Tirzepatide is an innovative medication that has recently gained prominence as one of the newest treatments for obésité. Originally developed for the management of type 2 diabetes, tirzepatide belongs to the class of GIP receptor agonists (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonists (glucagon-like peptide-1). This dual action uniquely positions tirzepatide as a treatment that simultaneously targets two intestinal hormones that play crucial roles in regulating blood sugar levels et métabolisme.

Mécanisme d'action

• GIP (Glucose-Dependent Insulinotropic Polypeptide): This hormone, produced in the intestine, slows gastric secretion and motility while stimulating insulin secretion. GIP receptors are also found on adipocytes (fat cells), suggesting that tirzepatide may help regulate lipid absorption as well.

• GLP-1 (Glucagon-like Peptide-1): Released by the intestine after food intake, GLP-1 prepares the body to utilize incoming nutrients by:

• Stimulating insulin secretion.
• Helping to maintain blood sugar balance.
• Promoting feelings of satiété.

According to Dr. Leonardi, this dual mechanism allows tirzepatide to not only stabilize blood sugar levels but also significantly influence satiété et fat metabolism.

Efficacy in Treating Obesity

Tirzepatide’s effectiveness in obesity treatment is based on multiple mechanisms:

1. Appetite Reduction: Tirzepatide exerts effects on the central nervous system to enhance satiety, thereby reducing the desire to eat, which facilitates a decrease in calorie intake.

2. Increased Sensation of Fullness: By slowing gastric emptying, tirzepatide prolongs the feeling of fullness after meals, effectively reducing overall food consumption.

3. Reduction of Cravings for High-Calorie Foods: Tirzepatide also helps diminish cravings for high-calorie foods that are consumed purely for pleasure.

Dosage and Contents

The typical dosage for tirzepatide is administered as a subcutaneous injection, and it is usually started at a low dose to minimize potential side effects, gradually increasing based on patient tolerance and clinical response. Dosage options currently include:

• 2,5 mg once weekly: This initial dose helps assess tolerance and adjust for optimal effectiveness.
• 5 mg once weekly: This dosage may be increased based on the physician’s assessment after evaluation of the patient’s response to therapy.
• 7,5 mg, 10 mg, et 15 mg once weekly: These doses provide options for further titration based on the individual’s needs and goals in managing obesity or blood sugar levels.

Each injection of tirzepatide includes excipients and preservatives suitable for the formulation and stability of the active compound.

This revolutionary treatment represents a new frontier in obesity management and continues to receive attention from the medical and scientific communities for its promising results and lower incidence of side effects compared to previous therapies.